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IHC VALIDATION IN CLINICAL SETTINGS; HOW LAB DEVELOPED 
ASSAYS DRIVE CLINICAL THERAPIES  
 
SARAH E. LANGLOIS  
ABSTRACT 
Diagnostic laboratory tests are critical to patient care as they help dictate the most 
appropriate treatments and procedures.  To that end, hospitals and laboratories must 
ensure their diagnostic assays are optimized so as to afford patients their best chance for 
recovery. The pathology laboratory at Boston Medical Center, like all testing labs, must 
validate their IHC protocols yearly according to ASCO/CAP guidelines. Furthermore, 
BMC has a diverse patient population similar to the Atlanta population-based study 
published by Lund, et al. in 2010. Based on the results of the yearly ASCO/CAP testing 
and compared with the results of the Atlanta study, it was found that BMC’s HER2 
testing was most likely not capturing all positive cases consistently. This prompted an 
optimization procedure for HER2 to be implemented. In addition to HER2 testing, BMC 
is looking at ways to optimize and implement PD-L1 IHC protocols as a way to identify 
those patients who might benefit from more targeted therapy. Methods: HER2 IHC was 
performed with an altered protocol to attempt a higher concordance rate with PhenoPath, 
a reference lab in Seattle, and the Atlanta study data. ER and PR validation IHC protocols 
were also performed to ensure adequate concordance with required yearly testing. 
Results: ER and PR protocols were found to be >95% accurate as compared to reference 
lab results. The new HER2 protocol yielded more vibrant staining results when compared 
  vi
to known positive reference data and previous BMC testing of the same sample. 
Discussion: Optimizing lab assays is a critical step in ensuring proper clinical therapies 
are being utilized. Regular testing of a lab’s IHC output must be continuously verified, 
and continued data collection of the improved HER2 protocol is needed to make sure 
appropriate standards are being met. Further testing of PD-L1 IHC protocols will be 
warranted to maintain maximum efficiency.  
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 1 
INTRODUCTION 
 
 Validated lab assays are critical to patient health as they help to ensure 
appropriate and effective treatment. Through years of research a number of biological 
therapeutic targets have been identified for more precise treatment than previously 
prescribed. In breast cancer, three receptors have been identified as therapeutic targets: 
ER, PR, and HER2. Treatment of breast cancer is determined by the patient’s subtype, 
with triple-negative cancers (those lacking all three) having the worst prognosis overall 
since current targeted drugs would be ineffective. Medicines that target receptor positive 
breast cancer have increased patient survival while decreasing disease recurrence. Other 
targets are currently being researched, such as the immune suppressor PD-L1. This 
receptor has been identified in a number of cancers, and will hopefully provide for a 
variety of targeted treatment options for affected patients.  
These precise medications are only prescribed if there is positive confirmation 
from the appropriate lab assay, namely IHC. It is therefore essential that lab assays be 
robust enough to capture the presence of these receptors so that efficient and effective 
treatments can be deployed. Laboratories need to ensure their protocols are optimized for 
accuracy and sensitivity. This is achieved by comparing results to a validated reference 
lab as well as maintaining ongoing protocol quality checks per ASCO/CAP guidelines. 
By having potent lab assays, doctors can be sure they have the information they need to 
give their patients the best clinical therapy available. Therefore, the focus of this study is 
validate the current ER and PR IHC protocols, optimize the HER2 IHC protocol, and 
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seek to begin development of a viable PD-L1 IHC protocol to service the patient 
population of Boston Medical Center.  
Estrogen Receptor  
 There are two variants of the estrogen receptor, ERα and ERβ. They are coded by 
different genes, ESR1 and ESR2 respectively on chromosome 6, but are very similar in 
structure and function. ER is a transcription factor that is activated by the binding of 
estrogen and can have an effect on multiple signaling pathways, to include ERK/MAPK, 
p38/MAPK, PI3K/AKT, and PLC/PKC [18]. Once activated, ER translocates to the 
nucleus and binds to genes that are activated by estrogen responsive elements (EREs). In 
ER positive cancer, ER is overexpressed which causes increased cell proliferation and 
tumor growth. 
Progesterone Receptor  
 The progesterone receptor is encoded by the PGR gene on chromosome 11 and 
results in two variants, PRα and PRβ. PRβ has an extra N-terminal domain called B-
upstream segment (BUS) which contains a third transcription activation function (TAF3) 
which results in both variants effecting on different genes [18]. PR is a transcription 
factor which is activated by the binding of progesterone. Like ER, an activated PR will 
bind to progesterone responsive elements (PREs) in the nucleus and induce transcription 
of targeted genes. Similarly, in PR positive cancer, PR is overexpressed and results in cell 
proliferation and tumor growth.  
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Human Epidermal Growth Factor Receptor 2 
HER2 is coded by the erb-b2 receptor tyrosine kinase 2 gene (ERBB2) on 
chromosome 17. Through the RAS-MAPK signaling pathway it promotes cell 
proliferation and inhibits cell death through the PI3/AKT/mTOR pathway [13]. 
Overexpression of HER2 results in increased cell proliferation and prevention of 
apoptosis through AKT enzymes. Therefore, in HER2 positive breast cancer, cells 
continue to proliferate without succumbing to programmed cell death which leads to 
tumor growth. HER2 overexpression is also implicated in some gastric cancers, however 
that is not the focus of this paper.  
Breast Cancer Incidence and Treatment  
 Breast cancer remains the most common cancer in women in the United States 
with 124.8 per 100,000 new cases being diagnosed in 2015 as reported by the CDC. For 
that same year the rate of death from breast cancer was 20.3 per 100,000 [2]. Generally, 
incidence of new disease increases with age with the average age at diagnosis being 61 
years. The most common type of breast cancer overall is ER+, representing about two-
thirds of all cases. White women tend to have the highest rates of breast cancer, however 
black women have a higher risk of death. This is partly due to the type of cancer more 
commonly found in black women: triple-negative. This type of breast cancer represents 
about 15% of all cases, except in premenopausal black women, where the number jumps 
to roughly 39% [8]. TNBC lacks overexpression of the three receptors, making hormone 
targeted therapy ineffective.  It tends to be more aggressive than receptor positive cancer 
and is also more prevalent in women diagnosed under 40 years of age. HER2+ cancers 
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also tend to be aggressive and represent about 20% of diagnoses [15]. Given these 
statistics it is vital that lab assays can accurately diagnose patients so they may be 
assigned effective, lifesaving treatment. 
Lab tests are preformed to determine if an individual’s cancer is ER, PR, and/or 
HER2 positive, and those results determine which treatment option would be most 
beneficial to the patient. For those with triple-negative breast cancer, treatment generally 
includes lumpectomy, mastectomy, radiation, and/or chemotherapy. For those with 
receptor positive cancer, targeted medicines have been developed which can help 
streamline therapy and improve patient survival. These treatments attack the cancer cells 
directly by targeting the receptor itself, leaving normal cells alone. Although the rate of 
new cancers is steady, the 5-year survival rate for breast cancer is 89.7%, and the death 
rate has continued to decrease [14]. 
This is partly due to more targeted therapies that focus on specific receptors. 
There are many FDA approved medications available for patients with ER+ and PR+ 
breast cancers, a common example being tamoxifen which blocks the estrogen receptor, 
and/or aromatase inhibitors, which halts production of estrogen. For those with HER2+ 
cancer, trastuzumab has been the standard treatment, usually in conjunction with 
additional drugs and chemotherapy. Trastuzumab works by binding to HER2 receptors 
and blocking the intracellular signaling that results in tumor proliferation. These 
therapeutics generally increase survival time and decrease disease recurrence.  For those 
with aggressive HER2+ cancer, these drugs are critical to reduce mortality. Prior to 
trastuzumab approval, HER2+ breast cancer had poor prognosis due to its fast-growing, 
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aggressive nature.  If someone has HER2+ cancer but it remains undetected, that patient 
is missing out on potentially lifesaving treatment. It is therefore critical to ensure the lab 
assays used to detect breast cancer subtypes are adequately sensitive so that effective 
treatment can be administered.  
Immunohistochemistry  
 The foundations of immunohistochemistry began with serum therapy, which used 
‘anti-toxins’ from animals to confer passive immunity, and the discovery of antigen-
antibody binding in the 1890’s [3]. Through the years, scientists worked to determine 
how to identify the correct antibodies that would adhere to the target antigen. In the early 
20th century, Dr. Paul Erlich’s Nobel prize-winning research demonstrated that antibody-
antigen binding was accelerated by heat and slowed by cold, and noted the high 
specificity of that binding. As the structure and chemistry of antibodies and antigens was 
discovered, labels were developed that would identify the targeted biochemical entities. 
Dr.  Michael Heidelberger has been credited as the first to add dye in a solution to 
effectively label an antibody-antigen complex [3]. At first, imunoglobulin G (IgG) was 
the most commonly used antibody as its structure contained an antigen binding site and a 
free site with which a label could be attached. The label is a peroxidase enzyme 
conjugated with DAB which is what allows the pathologist to view the now colored 
antigen under a microscope and diagnose the sample. These previous decades of research 
has led us to the steps BMC uses today to conduct IHC assays for patient diagnosis.   
Patients’ surgical samples are sent to the pathologist for microscopic observation 
of histological changes. For all invasive breast carcinomas found, an IHC test is 
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performed to determine the presence (or absence) of ER and PR, and/or overexpression 
of HER2 in the patient. There are two types of IHC: direct and indirect. In the direct 
method, a labeled antibody is used that will bind to the target antigen directly. Excess 
antibodies are washed away and DAB is added. DAB acts as the reporter conjugate and 
adheres to the target cell via the labeled antibody to allow for visual confirmation of the 
affected cells. This method is appropriate if there is a sufficient number of primary 
antibodies available. During the development of IHC, it was discovered that antibodies 
could also be thought of as antigens. This led to the development of the indirect method. 
In the indirect method, a primary, unlabeled antibody is added to the sample so that it 
binds to the target antigen. A secondary, labeled antibody is then added to the sample 
which will bind to the primary antibody. Just like the direct method, DAB is then added 
which will allow for visual confirmation of the target antigen should it be present.  
If the target antigen, for example HER2, is overexpressed in the tumor cells being 
tested, the affected cells will look stained. This allows the pathologist to visually observe 
the presence of a specific target antigen and make a final diagnosis. There are two main 
components to IHC protocols: preparing the sample and subsequent staining. Excised 
tissues from biopsies or other surgical procedures are embedded in formalin-fixed 
paraffin blocks to preserve the specimen until they can be stained. Once the sample is 
ready to be tested the paraffin block is sliced for mounting on a glass slide. The paraffin 
is then removed and the stain with the appropriate antibody clone is administered.   
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IHC Breast Cancer Protocols  
 BMC employs specific IHC protocols to determine which type of breast cancer is 
present in a given patient. These protocols must be validated on an ongoing basis to 
ensure the lab assay is functioning at an optimal level. The ASCO/CAP have determined 
a set of guidelines for validating ER, PR, and HER2 assays to be implemented in 
laboratories. In 2007, the ASCO/CAP developed a set of guidelines for validating HER2 
outcomes followed in 2008 by guidelines for ER and PR [5]. Both organizations 
convened an expert panel of researchers to review literature and evidence to determine 
recommendations for laboratory best practices. Input from industry experts and 
individuals from the FDA were taken into consideration to develop a comprehensive 
approach to breast cancer subtype validation. These guidelines are not updated annually, 
so testing labs must take into account their specific patient population and any new 
evidence that may come to light due to ongoing research.  
General considerations for ER and PR validation include limiting the time from 
tissue excision to fixation so as to preserve the integrity of the specimen and keeping 
slides stored for not more than six weeks before they are stained and evaluated. For an 
initial assay validation the lab must compare its results against an already validated 
procedure from a different reference lab according to ASCO/CAP standards. The 
validating lab must test ≥40 positive and ≥40 negative cases and demonstrate ≥90% 
concordance for positive results and ≥95% for negative results. A positive test for ER and 
PR is defined as having ≥1% of reactive cells. Pathologists who will be visually 
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diagnosing samples must also have their skills validated and demonstrate ≤ 2 incorrect 
assessments based on the 40 sample sets [4].  
 For ongoing validation, labs must calculate their results and compare them to 
approved ASCO/CAP standards at least twice annually. Generally ER+ results should 
represent about 70-85% of cases, while PR+ results should represent about 60-75% of 
cases. If those rates are not met, cases should be reviewed against age and histologic 
parameters to identify potential outlier influence, e.g. a sample population consisting of 
mostly younger individuals who are more likely to present with TNBC. Additionally, if 
gene expression analyses is performed then concordance must be ≥ 95% against the ER 
and PR IHC results [4].  
 Testing for HER2 follows the same considerations as ER and PR testing regarding 
tissue fixation time and slide storage. From here the validation protocols as outlined by 
the ASCO/CAP vary from the previously described methods. HER2 results are graded as 
0-1+, 2+, or 3+. Negative results (0-1+) are indicated by no staining or very weak, 
incomplete staining present in the sample. Borderline results (2+) are indicated by 
complete membrane staining that is weak or non-uniform. Circumferential differentiation 
is present in at least 10% of cells but less than 30%. Positive results (3+) are indicated by 
intense uniform membrane staining in at least 30% of cells.  
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Figure 1: IHC HER2 results of increasing gradient.                                                                                                                
(Image:her2support.org/pdf/her2testresults) 
 
 For borderline cases (2+), FISH is performed to determine if HER2 gene 
amplification (located on chromosome 17) is present so that a definitive diagnosis can be 
made. FISH technique utilizes colored probes which detect excessive amplification of a 
particular target gene. According to ASCO/CAP standards, the ratio of HER2 to CEP17 
is evaluated. A positive FISH test for HER2 has a ratio > 2.2, an equivocal test has a ratio 
of 1.8 – 2.2, and a negative test has a ratio < 1.8. Unlike ER and PR assays, HER2 
outcomes are not binary but are instead on a gradient scale. Therefore, there is inherent 
variability in HER2 testing. These variations can be a result of different equipment used 
and how it is calibrated, differing fixation methods, materials used, and skill of staff. 
Labs conducting HER2 testing must evaluate their results two to four times per year in 
comparison to the results of a validated reference laboratory. ASCO/CAP requires a 95% 
concordance rate for lab assay validation protocols [20].  
 BMC uses Phenopath as a reference lab for IHC protocols. Phenopath is a 
pathologist run diagnostic lab located in Seattle, Washington which was recently acquired 
by Quest Diagnostics in September of 2018. They hold an accreditation from the College 
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of American Pathologists for a wide array of testing services which includes IHC and 
FISH. Although they must continuously monitor their lab functions to maintain 
accreditation, they are approved as a reference for comparison of testing results. This 
comparison is not blinded, however a detailed report of sample information is compiled 
so that retesting can be performed should statistically abnormal results present in the 
diagnostic lab.  
 BMC’s original HER2 IHC assays were found to be lacking when compared with 
assays performed by PhenoPath as displayed in the images below:  
 
Figure 2: IHC assay for HER2 from BMC (left), score 1+ vs. PhenoPath (right), 
score 3+. 
 
The image on the left is a breast cancer sample that was given a HER2 score of 1+, while 
the image on the right is the same sample with a score of 3+ from PhenoPath. A 
discrepancy like this could drastically change a patient’s treatment regime and 
subsequent prognosis if left unchecked. This illustrates the importance of assay validation 
and led to a reevaluation of BMC’s HER2 IHC protocol with the goal of better alignment 
to PhenoPath’s results.  
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 The pre-optimized HER2 assay results also showed a difference from the Atlanta 
population-based study performed by Lund, et al. published in 2010 as displayed in Table 
1. BMC patient IHC results from the previous year were tallied and compared to the 
results of the Atlanta study. Fortunately, the ER+ and PR+ rates are aligned with those 
from the Atlanta study which indicates those BMC assays are on target. Ideally, the rate 
of HER2 positive patients would be about 15% and match the Atlanta results closely as 
the tested population is similarly broken down by race, namely African-American and 
Caucasian. 
Table 1: ER, PR, and HER2 IHC data from BMC compared to Atlanta study.  
 BMC  Atlanta Study (Lund, et al) 
Caucasian  34.5% 46% 
African-American  42.8% 48% 
Unknown  19.3% N/A 
Other 3.4% 6% 
ER positive  78%  73.9%  
PR positive  67%  63.5%  
HER2  3+ 9%  10.7% 
HER2  2+ 5%  13.5% 
HER2 1+ 16.8% 15.4% 
HER2 0 68.5% 58.3% 
HER2 Positive  12% 14.4% 
 
The BMC data as shown in Table 1 exhibits a consistently lower HER2 positive number 
as compared to the Atlanta study data, an area with similar demographics. This, in 
conjunction with the results as shown in Figure 2, prompted a review of the HER2 
protocol with a goal of aligning subsequent results to the reference lab and study data 
outcomes.  
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PD-L1 
 An emerging therapeutic target currently being studied is PD-L1. This protein 
receptor, located on antigen presenting cells, binds to PD-1, a member of the CD28 
family, which is expressed on activated T, B, and natural killer cells [21]. PD-1/PD-L1 
has a negative co-stimulatory effect on both naïve T cells and cytotoxic T cells during an 
immune response [10]. In healthy individuals this response maintains immune 
homeostasis by shutting down activated T cells, thereby preventing cellular damage and 
potential autoimmune disease. This downregulation is also a critical factor in maintaining 
maternal tolerance of a fetus during pregnancy. The presence of this immune suppressor 
has been found in a variety of cancers, namely non-small cell lung cancer and melanoma. 
When present, PD-L1 is typically overexpressed in these cancers which shuts down the 
immune response prematurely and allows the tumor cells to evade destruction. This is 
achieved by inducing T-cell exhaustion, and increased PD-L1 expression is generally 
associated with a poor prognosis.  
 The Blueprint project has worked to identify the most effective clones for use in 
PD-L1 IHC. In the first Blueprint phase, non-small cell lung cancer specimens were used 
to test staining with four different clones: 22C3, 28-8, SP142, and SP263. Researchers 
found that three of the four clones showed consistent staining of tumor cells, whereas the 
remaining clone, SP142, consistently displayed fewer cells expressing PD-L1 by 
comparison. In the second phase of the study researchers stained 81 lung cancer samples 
with five different clones: 22C3, 28-8, SP142, SP263, and 73-10. The results mirrored the 
previous phase, with SP142 showing the least sensitivity and 73-10 showing the greatest 
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sensitivity. Clones 22C3, SP263 and 28-8 were deemed relatively interchangeable. Using 
this data, laboratories must determine which clone would be most appropriate for their 
situation, taking into account the type of cancer being tested, the brand of instruments 
used, and the cost of the clones themselves [19]. 
 Using this background information, BMC aims to adopt an efficient and cost 
effective PD-L1 assay as well as optimize their breast cancer IHC protocols. For now, 
BMC will have to utilize resources from other medical institutions throughout Boston in 
order to implement a working PD-L1 protocol. PD-L1 inhibitors are a fairly new class of 
drugs that are being developed by various pharmaceutical companies. With a suitable 
PD-L1 assay in place, BMC will be better able to offer physicians the correct information 
for them to prescribe the most cutting edge treatment to those in need. In the meantime, 
the breast cancer IHC assays that are currently being used for patient diagnoses need to 
be continuously examined to ensure compliance and optimized results. Given the 
effectiveness of targeted treatment against ER+, PR+, and HER2+ breast cancers it is the 
responsibility of diagnostic laboratories to ensure their assays are able to identify those 
patients who would benefit most. This is especially true given the aggressive nature of 
HER2+ breast cancer. Patient quality of life and survival is the ultimate goal of assay 
optimization, and the impacts of which will eventually affect all of us in one way or 
another.  
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METHODS 
 
ER 
 
 For ER validation, TMAs were created from 100 patient samples from 2014 – 
2018. To create the TMAs a puncher was used to remove a circular section from each 
fixed tissue sample that was to be tested. That circular section was then transferred into 
one well of the TMA block. Each TMA block contains 12 total wells, with one well 
containing smooth muscle as a control. This left 11 samples per TMA, which resulted in 
10 TMA blocks. Slides were cut from each TMA paraffin block to be prepped for IHC. 
BMC used automated protocol #976 on the Ventana Benchmark Ulta immunostainer with 
clone SP1. Epitope retrieval was performed using CC1 reagent, with a maximum 
incubation of 36 minutes at 95°C. Antigen targeting was performed using clone SP1. 
Slides were incubated for 8 minutes at 20°C. Linker is added and slide is incubated for 8 
minutes, followed by DAB application and additional 8 minutes incubation. Finally, 
chromogen is added, and slide is incubated for 8 minutes. Linker, DAB, and chromogen 
incubation is performed at 20°C. Slides are then visually inspected. Tonsil and cervix 
tissue was used for positive controls, while other tonsil tissue was used for negative 
controls.  
PR 
For PR validation, TMA were created from 91 patient samples from 2014 – 2018 
as previously described. Each TMA block contained 11 samples resulting in 9 TMA 
blocks.  Slides were cut from the each TMA paraffin block to be prepped for IHC.  BMC 
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used protocol #949 on the Ventana Benmark Ulta immunostainer with clone 1E2. 
Epitope retrieval was performed using CC1 reagent, with a maximum incubation of 56 
minutes at 95°C. Antigen targeting was performed using clone 1E2. Slides were 
incubated for 8 minutes at 37°C. Linker is added and slide is incubated for 8 minutes, 
followed by DAB application and additional 8 minutes incubation. Finally, chromogen is 
added, and slide is incubated for 8 minutes. Linker, DAB, and chromogen incubation is 
performed at 20°C. Slides are then visually inspected. Tonsil and cervix tissue was used 
for positive controls, while other tonsil tissue was used for negative controls.  
HER2 
For HER2 optimization, TMAs were created from 125 patient samples from 2014 
– 2018 as previously described. Each TMA block contained 11 samples, resulting in 12 
TMA blocks. Slides were cut from each TMA paraffin block to be prepped for IHC. 
BMC used protocol #1391 on the Ventana Benchmark Ulta immunostainer with clone 
4B5. Previous protocols had epitope retrieval performed with CC1 for 8 minutes at 95°C. 
In an effort optimize results, multiple protocols were run with different incubation 
periods, both during the epitope retrieval and antibody binding steps.  
Table 2: Experimental Incubation Times for HER2 IHC.  
Epitope Retrieval 
 Incubation at 95°C (minutes)  
Antibody Incubation at 37°C 
(minutes)  
8 (original protocol)  16 (original protocol)   
20  12 
36  8  
36  12 
52  12  
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Staining procedures remained the same for all variations tested. Hemotoxylin II 
was added and the slide was incubated for 12 minutes followed by Bluing reagent and an 
additional 12 minute incubation. Both staining steps were performed at 20°C. TMAs 
from resected breast carcinomas were used as controls. 
Data Collection  
 After validation protocols were run patient data was obtained from CoPath, 
BMC’s internal records database. Race and subtype results were collected and organized 
into a spreadsheet for subsequent evaluation. This will continue to serve as a prospective 
database for all incoming test results to ensure breast cancer IHC assays remain valid.  
PDL1 
  Preliminary IHC testing was performed on tonsil tissue with the Ventana 
Benchmark Ulta immunostainer using clone E1L3N. Multiple incubation times of epitope 
retrieval were performed to determine which would yield optimal results as displayed in 
Table 3. The incubation time for antibody binding was 12 minutes at 36°C for all samples 
tested.  Staining procedures were the same for all, with two DAB application steps 
incubating for 8 minutes at 37°C each.  
Table 3: Epitope Retrieval Times for PD-L1 IHC.  
Epitope Retrieval 
 Incubation at 100°C (minutes)  
24  
32 
40  
48  
56  
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RESULTS 
 
 
ER 
BMC compares its results to PhenoPath. Out of 50 known positive cases tested, 
all 50 were found positive. Out of 10 known weak positive cases tested, all 10 were found 
to be weak positive. Out of 40 known negative cases tested, all 40 were found to be 
negative. Therefore, the BMC protocol returned 100% correlation with PhenoPath’s 
accuracy on all cases tested. These results satisfy the re-validation requirement as set 
forth by ASCO/CAP.  
 
Figure 3: ER IHC Results – positive, weak positive, and negative (from left to right).  
 Figure 3 shows examples of the three different IHC results from the ER protocol. 
The image on the left shows distinct, dark staining which indicates a positive sample. The 
middle image shows inconsistent, light-colored staining indicating a weak positive 
sample. The image on the right shows no staining at all, which indicates a negative 
sample.  
PR 
Results from BMC’s PR assay were compared to PhenoPath. Out of 41 known 
positive cases tested, all 41 were found positive. Out of 10 known weak positive cases 
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tested, all 10 were found to be weak positive. Out of 40 known negative cases tested, all 
40 were found to be negative. Therefore, the BMC protocol returned 100% correlation 
with PhenoPath’s accuracy on all cases tested. These results satisfy the re-validation 
requirement as set forth by ASCO/CAP.   
 
Figure 4: PR IHC Results – positive, weak positive, and negative (from left to right).  
 Figure 4 shows examples of the three different IHC results from the PR protocol, 
which are very similar to the ER results as shown in Figure 3. The left image shows dark, 
consistent staining indicating a positive sample. The middle image shows sparse staining 
which indicates a weak positive sample. The right most image shows no staining, which 
indicates the sample is negative.  
HER2  
 Figure 5 shows the results of the various incubation times tested. The 8ep/16ab 
and 20ep/12ab protocols were too weak and did not match the PhenoPath result as shown 
in the bottom right image. Use of these protocols would result in positive samples not 
being detected.  Conversely, the 36ep/12ab and 52ep/12ab yielded results that were too 
strong as there is more prominent staining compared to the PhenoPath control. If used in 
practice, these protocols would result in too many false positives. It was therefore noted 
that the 36ep/8ab incubation configuration (upper right image) yielded results most 
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closely resembling that of PhenoPath, and was subsequently deemed the optimal 
protocol.  
 
Figure 5: HER2 IHC results from various incubation times. (Ep = epitope retrieval 
time; ab = antibody binding time).  
 
Using the optimized protocol, there were 33 positive (3+) cases from the IHC 
protocol which was verified by FISH. This demonstrates 100% concordance of positive 
screening tests. There were 30 known negative cases, 29 of which were verified by FISH 
as being non-amplified. This demonstrates 96.7% concordance of negative screening 
tests. Therefore, overall concordance for all HER2 was 98.4%. This satisfies the 
validation requirement as set forth by ASCO/CAP, and demonstrates an optimized 
protocol.  
 The images below show the increase in staining as a result of the optimized 
protocol. The left image, from BMC, shows similar staining patterns as the PhenoPath 
stain on the right. This sample is now rightly classified as HER2 3+. 
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Figure 6: IHC assay for HER2 from BMC’s new protocol (left), score 3+ vs. 
PhenoPath (right), score 3+. 
 
 This new optimized protocol was put into practice starting December 19, 2018. 
Since that day, breast cancer subtype data has been recorded and organized according to 
race. To date, 53 total patient cases have been examined which have yielded HER2 
scoring results as displayed in Table 2.  
Table 4: HER2 scoring broken down by race.  
HER2 Score  African-
American  
Caucasian  Asian/Pacific 
Islander 
Unknown  
HER2 
negative 
(score 0 or 
1) 
15 9 2 5 
HER2 
2+/FISH 
Negative  
5 1 1 6 
HER2 
2+/FISH 
Positive 
1 1 0 0 
HER2 3+ 4 1 1 1 
 
There have also been four triple-negative cases found since the implementation of the 
new protocol. Two are African-American, one is Caucasian, and one is of unknown race. 
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The data collected so far shows a HER2 3+ rate of about 13%. This is an improvement 
over the previous rate of 9%, however data collection will need to be continued 
throughout the year in order to obtain a complete picture of how well the assay is 
performing.  
PDL1 
 The incubation configuration of 48 minutes for epitope retrieval and 12 minutes 
of antibody binding yielded the desired results as shown in Figure 6. There is strong 
staining in the squamous cells on the left side of the image indicating PD-L1 
overexpression and weak staining in the macrophages on the right side of the image. 
More tests will need to be conducted with different tissue types, namely lung and 
melanoma, however this is a promising first step in BMC’s objective to run a PD-L1 IHC 
protocol on site.  
  
 Figure 7: PD-L1 staining of tonsil tissue.  
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DISCUSSION 
 Lab assay validation is a pivotal component of patient care as it informs 
healthcare professionals how best to treat their patients. Immunohistochemistry remains 
an efficient and accurate way to identify molecular targets for precise treatment. It has the 
capacity to test for a number of molecular entities simply by changing the antibody clone 
and adjusting for optimal incubation time and temperature. This adaptability makes IHC 
a potent tool which can be adapted to assess an array of maladies. With validated IHC 
protocols, pathology labs can diagnose patients quickly so that proper treatment can be 
administered.  
PD-L1 remains a promising therapeutic target with multiple pharmaceutical 
companies working on development of applicable medicines. BMC’s preliminary IHC 
testing on PD-L1 shows promise, however more assays need to be run in order to 
implement a working protocol for patient samples. Next steps will include comparison of 
reference samples performed by PhenoPath on melanoma and non-small cell lung cancer 
tissues against tests run at BMC. Once BMC is able to demonstrate consistent proficiency 
with the optimal PD-L1 protocol and sufficient concordance according to ASCO/CAP 
guidelines, the lab will be able to implement the procedure as part of their diagnostic 
program. Patient data will need to be continuously collected and analyzed to ensure 
ongoing veracity of results.  
The ER and PR protocols have maintained their validated status as demonstrated 
by the high level of concordance with the known reference lab samples, so there were no 
changes needed. The newly optimized HER2 IHC protocol has so far demonstrated better 
 23 
results than previous protocols. This was achieved by testing various incubation 
configurations to find the result that most closely resembled that of PhenoPath. By 
increasing the epitope retrieval incubation time from 8 minutes to 36 minutes during the 
epitope retrieval step, more antigen was present for antibody binding, which in turn 
yielded a stronger stain than previously shown in other BMC results. Conversely, it was 
also important to make sure the stain was not too strong which would result in false 
positives. This was achieved by reducing the antibody binding incubation time from 16 
minutes to 8 minutes. This toggling of incubation times highlights the nuanced nature of 
HER2 IHC. Unlike the binary outcomes of ER and PR (i.e. positive and negative), HER2 
IHC can be open to interpretation, most notably if the sample shows a borderline result 
(score 2+). This, coupled with the possible variations of different pathologists’ 
interpretations, underlines the gravity of having accurate, validated IHC protocols in 
order to eliminate erroneous testing outcomes.  
Altering the incubations times is a relatively small change which has aligned 
BMC to ASCO/CAP guidelines and will provide physicians the correct information to 
care for their patients. It is no more work intensive than previous protocols, which will 
help maintain short turnaround time in the lab, about 24 hours from surgery. Since the 
new protocol was only implemented three months ago, continued data analysis will need 
to be conducted in order to maintain sufficient assay potency. This involves periodically 
comparing HER2 IHC results to PhenoPath as well as keeping a log of HER2 results as 
found in the BMC patient population. Since implementation there have only been 53 
patients tested for HER2. Right now, the breakdown is generally in line with expected 
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outcomes, however more data points need to be collected in order to gain a complete 
picture of testing accuracy.  
 Cancer affects everyone, either directly or indirectly, and it is imperative that 
pathology departments are equipped to properly diagnose affected individuals. These lab 
assays are replied upon to give accurate results so that targeted therapy can be prescribed 
to those who would benefit. Precision medicine has gained a lot of attention recently as it 
promises to streamline therapy and improve survival. Traditional chemotherapy can be 
effective, but it is plagued with unpleasant side effects and a diminished quality of life for 
those undergoing treatment. Given the prevalence of cancer, it is in society’s best interest 
for laboratories to maintain optimized standards for diagnostic assays and for scientists to 
remain committed to advancing targeted clinical therapies for continued patient survival.  
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